EMA Recommends Extension of Indications for Pembrolizumab
New indication concerns the first-line treatment of metastatic MSI-H or dMMR colorectal cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and Safe in Recurrent Glioblastoma
Patients received intratumoural administration of ipilimumab plus nivolumab that was followed by intracavitary nivolumab plus nivolumab given intravenously
TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in HPV-Positive Malignancies
This combination changes “cold” tumour microenvironments to “hot” in Human Papillomavirus-positive malignancies
Promising Results Are Provided by Tebentafusp in Metastatic Uveal Melanoma
Metastatic uveal melanoma is a treatment-refractory tumour that is associated with poor prognosis and poses an urgent need for new treatments
Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma
Quality of life, as evaluated by patient reported outcomes, was an exploratory endpoint of CheckMate 743
Survival According Circulating Tumour DNA Status in the Study of Adjuvant Atezolizumab for High-Risk Muscle Invasive Urothelial Cancer
Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy
The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint Inhibitors in Patients with MSI-H or dMMR Tumours
Immune checkpoint inhibitor treatment is used for tumours with microsatellite instability high or mismatch repair deficiency but not all of these patients respond
Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint Inhibition
Not all eligible patients respond to treatment with an immune checkpoint inhibitor
Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint Inhibitor Treatment in Patients with Non-Small Cell Lung Cancer
Pleural effusion was associated with worse patient characteristics, poorer survival and higher early death rates
Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination Treatment
Life-threatening adverse events have been reported in some patients following immune checkpoint inhibitor treatment for cancer
Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma
Data from a propensity-matched survival analysis
Rates of Ocular Toxicity Are Low Following Immune Checkpoint Inhibition
Immune-related adverse events due to checkpoint inhibitor treatment can affect any organ and may be linked to ocular adverse events